Tags

Type your tag names separated by a space and hit enter

Screening for hypogonadism in diabetes 2008/9: results from the Cheshire Primary Care cohort.
Prim Care Diabetes. 2012 Jul; 6(2):143-8.PC

Abstract

AIM

There is increasing awareness of hypogonadism in men with type 2 diabetes but limited data from Primary Care.

SUBJECTS AND METHODS

The anonymised records of 6457 male patients aged 18-80 years with diabetes were accessed. Within the last 2 years 391 men (6.0% of total) underwent measurement of serum testosterone. Data search was performed through the centralised data facility afforded by EMIS®, the majority GP systems provider in Cheshire.

RESULTS

4.4% of type 2 diabetes men screened were frankly hypogonadal with a serum total testosterone of less than 8.0 nmol/l. For borderline hypogonadism (serum total testosterone 8-11.99 nmol/l) the proportion of type 2 diabetes men rose to 32.1%. Age adjusted mean (geometric) testosterone was lower in men with type 2 diabetes (13.6 nmol/l 95%CI: 13.1-14.2) vs type 1 diabetes (17.9 nmol/l; 95%CI 15.2-21.0), F=10.3; p=0.0014. For those screened age adjusted body mass index (BMI) was greater in type 2 diabetes at 30.7 (30.1-31.3) vs 28.4 (26.1-30.6)kg/m(2) in type 1 diabetes (F=4.3; p=0.04). Multiple linear regression analysis indicated that there was a statistically significant interaction (P=0.014) between BMI and diabetes type in their relation with log testosterone. For persons with type 1 DM and type 2 DM, testosterone can be expected to decrease by 6% (P=0.002) and by 1% (P=0.002) respectively, for every one unit increment in BMI.

CONCLUSIONS

There is manifestly a subset of men with diabetes and androgen deficiency who could benefit from testosterone replacement. BMI has an independent influence on androgen status.

Authors+Show Affiliations

Cardiovascular Sciences Research Group, Core Technology Facility, University of Manchester, 46 Grafton Street, Manchester, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21982717

Citation

Anderson, Simon George, et al. "Screening for Hypogonadism in Diabetes 2008/9: Results From the Cheshire Primary Care Cohort." Primary Care Diabetes, vol. 6, no. 2, 2012, pp. 143-8.
Anderson SG, Heald A, Younger N, et al. Screening for hypogonadism in diabetes 2008/9: results from the Cheshire Primary Care cohort. Prim Care Diabetes. 2012;6(2):143-8.
Anderson, S. G., Heald, A., Younger, N., Bujawansa, S., Narayanan, R. P., McCulloch, A., & Jones, H. (2012). Screening for hypogonadism in diabetes 2008/9: results from the Cheshire Primary Care cohort. Primary Care Diabetes, 6(2), 143-8. https://doi.org/10.1016/j.pcd.2011.07.006
Anderson SG, et al. Screening for Hypogonadism in Diabetes 2008/9: Results From the Cheshire Primary Care Cohort. Prim Care Diabetes. 2012;6(2):143-8. PubMed PMID: 21982717.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Screening for hypogonadism in diabetes 2008/9: results from the Cheshire Primary Care cohort. AU - Anderson,Simon George, AU - Heald,Adrian, AU - Younger,Novie, AU - Bujawansa,Sumudu, AU - Narayanan,Ram Prakash, AU - McCulloch,Alan, AU - Jones,Hugh, Y1 - 2011/10/05/ PY - 2010/12/31/received PY - 2011/07/18/revised PY - 2011/07/29/accepted PY - 2011/10/11/entrez PY - 2011/10/11/pubmed PY - 2012/9/18/medline SP - 143 EP - 8 JF - Primary care diabetes JO - Prim Care Diabetes VL - 6 IS - 2 N2 - AIM: There is increasing awareness of hypogonadism in men with type 2 diabetes but limited data from Primary Care. SUBJECTS AND METHODS: The anonymised records of 6457 male patients aged 18-80 years with diabetes were accessed. Within the last 2 years 391 men (6.0% of total) underwent measurement of serum testosterone. Data search was performed through the centralised data facility afforded by EMIS®, the majority GP systems provider in Cheshire. RESULTS: 4.4% of type 2 diabetes men screened were frankly hypogonadal with a serum total testosterone of less than 8.0 nmol/l. For borderline hypogonadism (serum total testosterone 8-11.99 nmol/l) the proportion of type 2 diabetes men rose to 32.1%. Age adjusted mean (geometric) testosterone was lower in men with type 2 diabetes (13.6 nmol/l 95%CI: 13.1-14.2) vs type 1 diabetes (17.9 nmol/l; 95%CI 15.2-21.0), F=10.3; p=0.0014. For those screened age adjusted body mass index (BMI) was greater in type 2 diabetes at 30.7 (30.1-31.3) vs 28.4 (26.1-30.6)kg/m(2) in type 1 diabetes (F=4.3; p=0.04). Multiple linear regression analysis indicated that there was a statistically significant interaction (P=0.014) between BMI and diabetes type in their relation with log testosterone. For persons with type 1 DM and type 2 DM, testosterone can be expected to decrease by 6% (P=0.002) and by 1% (P=0.002) respectively, for every one unit increment in BMI. CONCLUSIONS: There is manifestly a subset of men with diabetes and androgen deficiency who could benefit from testosterone replacement. BMI has an independent influence on androgen status. SN - 1878-0210 UR - https://www.unboundmedicine.com/medline/citation/21982717/Screening_for_hypogonadism_in_diabetes_2008/9:_results_from_the_Cheshire_Primary_Care_cohort_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1751-9918(11)00077-5 DB - PRIME DP - Unbound Medicine ER -